伴t（11；19）（q23；p13．1）恶性血液病的临床和实验室特征  

Clinical and laboratory investigation of hematological malignancies with t（11;19）（q23;p13.1）

作　　者：谭丽[1] 刘芯[1] 曾金财 杨少江[1] 吴晓鸿[1] 

机构地区：[1]广州医科大学附属第一医院海印院区肿瘤血液中心,510230

出　　处：《白血病．淋巴瘤》2015年第1期58-60,共3页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金（81100379）

摘　　要：目的探讨伴t（11；19）（q23；p13．1）恶性血液病的临床及实验室特征。方法分析1例血液病患者资料，其骨髓细胞24h培养后按常规方法制备染色体，用R显带技术进行细胞遗传学分析。结果该例患者核型为t（11；19）（q23；p13．1），确诊为急性髓系白血病（AML）-M4c.应用MA方案化疗后患者未获完全缓解。结论t（11；19）（q23；p13．1）是一类很独特的白廊病亚型有关的易位，为少见的非随机染色体易位，其临床预后差。Objective To investigate the clinical and laboratory characteristics of hematological malignancies with t（11;19）（q23;p13.1）. Methods Chromosome specimens of bone marrow cell from a patient with hematological malignancy were collected. After short-term cuhure, and chromosome karyotype analysis was carried out by R banding technique. Results The chromosome karyotype of the patient diagnosed with AML M4c was t （11;19）（q23;p13.1）. The patient did not obtain complete remission after application of MA regimen chemotherapy. Conclusions t（11;19）（q23;p13.1） translocation is a rare and recurring chromosome abnormality, which is related with a specific type of AML. The prognosis of the AML patients with this chromosome ahnormality is poor.

关 键 词：染色体 易位 细胞遗传学 恶性血液病 

分 类 号：R733.7[医药卫生—肿瘤]